MedTrace Logo

Lynparza

Drug

Drug Profile

Lynparza is the brand name for olaparib, a poly ADP-ribose polymerase (PARP) inhibitor used across multiple BRCA/HRR-associated cancers. Its indications include ovarian, fallopian tube, peritoneal, breast, pancreatic, and prostate cancers in specific biomarker-defined settings. The FDA first approved Lynparza on December 19, 2014.

Drug Class
Poly ADP-ribose polymerase (PARP) inhibitor
Approval Status
FDA approved; first approved December 19, 2014.
Mechanism of Action
Inhibits PARP enzymes involved in DNA transcription/repair and exploits DNA damage response deficiencies such as BRCA mutations.
Brand Names
  • Lynparza
Indications
  • \Ovarian/fallopian tube/primary peritoneal cancer\
  • \Breast cancer\
  • \Pancreatic cancer\
  • \Prostate cancer\

Related News

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

FDA Grants Fast Track Designations for Two Breast Cancer Therapies

The FDA has granted fast track designation to ART6043 plus olaparib for germline BRCA-mutated HER2-negative breast cancer and to BriaCell's Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer, both addressing significant unmet medical needs.

Related Clinical Trials

NCT ID Title Status Phase
NCT04041128

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

 COMPLETED EARLY_PHASE1